Abbott Announced That The Us Food And Drug Administration (Fda) Has Granted Breakthrough Device Designation To Investigate The Use Of Its Deep Brain Stimulation (Dbs) System In Treatment-Resistant Depression (Trd), A Form Of Major Depressive Disorder (Mdd). Breakthrough Device Designation Expedites The Review Of Innovative Technologies That Can Improve The Lives Of People With Life-Threatening Or Irreversibly Debilitating Diseases Or Conditions.Abbott'S Dbs System Is A Personalized, Adjustable Therapy That Involves Implanting Thin Wires
